HONG KONG, August 11, 2021 / PRNewswire / – Enabled June 10, 2021, the National Health Commission, at the head of eight ministries and commissions, published the “Opinion on the dissemination of the special rectification work plan to combat illegal medico-aesthetic services.” On August 9, 2021, ‘People’s Daily ‘ published an article titled – ‘The medico-aesthetic sector must obtain the best effects and prevent harmful consequences.‘
The imported product – Letybo (botulinum toxin type A for injection) is a medico-aesthetic product manufactured by South Korea Hugel Inc. Bain Capital, a well-known international private equity fund, is the majority shareholder of Hugel Inc in South Korea. Beijing Meiyan Space Biomedicine Co., Ltd., a subsidiary of Sihuan Pharmaceutical, serves as the exclusive distributor of the product through China, has long been committed to becoming a major player in medical aesthetics in the China and obtained official product approval for Letybo of the National Administration of Medical Products of China in October 2020, thus becoming the first pharmaceutical laboratory to obtain approval for this type of product from South Korea. As a contributor of “positive energy” to from China medico-aesthetic, Sihuan Pharmaceutical has actively and conscientiously responded to the special directives of the eight ministries and commissions to “combat illegal medical-aesthetic services”.
Sihuan Pharmaceutical, like many manufacturers of medical aesthetic products, actively promotes the “positive energy” associated with from China medico-aesthetic industry. However, the company has fallen victim to products imported through illegal channels, which not only cause physical and mental injury to those seeking medico-aesthetic services, but also severely hamper the sustainable development of the company. from China medico-aesthetic industry.
Sihuan Pharmaceutical will actively cooperate with all relevant government departments to investigate the root causes and provide strong evidence to assist in the firm crackdown on the smuggling of illegal products, manufacture and sale of illegal products, as well as the transportation of products. illegal, while working hard to urge all relevant Korean companies to respect and cooperate with the policies of the Chinese government. This can be achieved by strictly monitoring the export channels, jointly preventing and combating smuggling while ensuring the legitimacy of Korean medical aesthetic products and protecting the interests of consumers in both countries.
Sihuan Pharmaceutical will also cooperate closely with the China Plastic Surgery Association Industry Development and Self-Discipline Committee, and actively participate in the “China Medical Aesthetic” mini program. We will also publish a list of compliant medico-aesthetic institutions that purchase products, and update it regularly to jointly promote the products while applying code scanning to verify the legal status of the product.
Sihuan Pharmaceutical, with colleagues from all walks of life who are concerned with from China the medico-aesthetic sector will make unremitting efforts to create a “true” and “positive” environment for from China medico-aesthetic industry.
Sihuan Pharmaceutical Holdings Group Ltd.
Founded in 2001 and listed on the Main Board of the Hong Kong Stock Exchange Limited in 2010, Sihuan Pharmaceutical Holdings Group Ltd. (“Sihuan Pharmaceutical” or the “Company”, together with its subsidiaries the “Group”) (HKSE: 00460. HK) is an international pharmaceutical company driven and driven by both innovation and generics, with a platform independent technology and research and development (“R&D”) leader, a rich global product pipeline and a mature and excellent sales system. By focusing on high growth therapeutic areas such as oncology, metabolic diseases, medical aesthetics, anti-infective, digestive system, cardiovascular and cerebrovascular diseases, Sihuan Pharmaceutical is building a leader in medical aesthetics and biopharmacy in China with a two-wheel drive strategy of independent innovation and research and incubation to cultivate new high-growth companies.
For more information about Sihuan Pharmaceutical, please visit the company website https://www.sihuanpharm.com/
SOURCE Sihuan Pharmaceutical Holdings Group Ltd.